[Form 4] Ikena Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing for ImageneBio, Inc. (f/k/a Ikena Oncology, Inc.) details initial insider ownership created by the 25 Jul 2025 closing of the two-step merger with Legacy Inmagene.

• Reporting person: Erin Butler, Principal Accounting Officer.
• Common stock received: 3,051 shares, recorded as an A (acquisition) transaction, not a market purchase. Post-transaction direct holding equals 3,051 shares.
• Stock options issued: option to buy 3,813 shares at an exercise price of $4.59, received via the same merger exchange. Vesting schedule: 25 % after one year, remainder in 36 equal monthly instalments; option expires 16 Oct 2027.
• Exchange ratio: every Legacy Inmagene share converted into 0.003051 ImageneBio shares.
• Corporate actions disclosed: completion of First and Second Mergers; company renamed to ImageneBio, Inc.; ticker indicated in the form as IMA.

No sales, open-market purchases or cash proceeds are reported. The filing simply establishes Butler’s equity stake and option grant resulting from the merger and signals that senior finance leadership is now aligned with new equity in the combined entity.

Positive

• Completion of merger officially converts Legacy Inmagene equity into ImageneBio shares, signalling corporate restructuring progress.
• Officer now holds equity and long-dated options, modestly improving management–shareholder alignment.

Negative

• None.

Insights

Equity Compensation Analyst

TL;DR: Officer received modest equity via merger; no market signal, neutral impact.

Because the shares and options stem from a share-for-share conversion, the transaction does not reflect discretionary buying or selling. The 3,051-share grant is immaterial relative to typical float sizes, and the 3,813 options carry a mid-single-digit strike, implying upside only if post-merger value creation exceeds $4.59. Vesting terms are standard 4-year 25/36 schedule, supporting retention. Overall, the filing confirms completion of the merger and aligns the accounting chief with equity but offers no directional insight into near-term price action.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Butler Erin

(Last) (First) (Middle)

C/O IMAGENEBIO, INC.

12526 HIGH BLUFF DRIVE, SUITE 345

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ImageneBio, Inc. [ IMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/25/2025		A(1)(2)		3,051	A	(1)(2)	3,051	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.59	07/25/2025		A		3,813		(3)	10/16/2027	Common Stock	3,813	(2)(4)	3,813	D

Explanation of Responses:

1. Received in exchange for 1,000,000 ordinary shares of Inmagene Biopharmaceuticals ("Legacy Inmagene") pursuant to Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Legacy Inmagene (the "Merger Agreement").

2. Under the terms of the Merger Agreement, on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "Merger"), with Legacy Inmagene surviving the Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). Upon the closing of the First Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. to ImageneBio, Inc.

3. 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.

4. Received in exchange for a stock option to acquire 1,250,000 shares of common stock of Legacy Inmagene with the exercise price of $0.014 per share pursuant to the Merger Agreement.

	/s/ Erin Butler	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ImageneBio (IMA) shares did Erin Butler receive?

She was issued 3,051 common shares on 25 Jul 2025 through the merger exchange.

What stock options were granted to Erin Butler in the Form 4?

An option covering 3,813 shares with a $4.59 exercise price, expiring 16 Oct 2027.

Was this an open-market purchase or sale?

Neither. The transaction code “A” shows an acquisition via merger, not a market trade.

What is the exchange ratio from Legacy Inmagene to ImageneBio?

Each Legacy Inmagene share converted into 0.003051 ImageneBio common shares.

Did the company change its name and ticker?

Yes. Following the merger, Ikena Oncology, Inc. was renamed ImageneBio, Inc.; the form lists ticker IMA.